Nucleome Therapeutics CSO appointment marks a significant leadership milestone as Nucleome Therapeutics names Dr. Michelle Morrow as its new Chief Scientific Officer, effective 23 February 2026. The appointment strengthens the company’s scientific leadership as it advances innovative therapies targeting the molecular causes of inflammatory diseases.
Experienced Biotech Leader Joins Nucleome
Dr. Michelle Morrow brings more than 20 years of experience in drug discovery, development, and R&D strategy across biotech and global pharmaceutical companies. Most recently, she served as CSO at Avacta Therapeutics. There, she led discovery and preclinical research and guided the oncology programme through candidate selection to IND approval.
Previously, she was SVP and Head of Innovation at invoX Therapeutics following its acquisition of F-star Therapeutics. At F-star, she held senior research roles and ultimately served as SVP, Head of Research. She also held scientific leadership positions at MedImmune, now part of AstraZeneca.
Dr. Morrow earned her PhD in Immunology from the University of Cambridge. In addition, she completed postdoctoral research in childhood leukaemia at the Institute of Child Health in London.
Strengthening Drug Discovery and Development
Dr. Mark Bodmer, CEO of Nucleome Therapeutics, emphasized that Dr. Morrow’s expertise in immunology and bispecific antibody therapeutics will be critical as the company advances its pipeline. Moreover, her experience in progressing drug candidates through the clinical pathway will support stronger portfolio decision-making.
He noted that her ability to translate complex scientific and development insights into clear strategies will enhance leadership across the organization. Therefore, the Nucleome Therapeutics CSO appointment signals a focused push toward clinical-stage advancement.
Advancing 3D Genomics in Inflammatory Disease
Nucleome Therapeutics is known for its breakthrough 3D genomics platform. This technology addresses the challenge of identifying molecular drivers of inflammatory disease from human genetics. By analyzing functional variants in the non-coding genome, the company uncovers novel targets and mechanisms that traditional approaches often miss.
Dr. Michelle Morrow stated that she joins the company at a pivotal stage. Nucleome is translating insights from the non-coding genome into a differentiated pipeline of potential new medicines. As a result, the company aims to develop first-in-class immunomodulatory therapies.
The company’s lead candidate, NTP464, is a novel monoclonal agonist antibody. It represents a new therapeutic principle for inflammatory diseases and is progressing toward IND-enabling studies.
Strategic Leadership for Future Growth
The Nucleome Therapeutics CSO appointment reflects the company’s ambition to accelerate innovation in inflammatory disease treatment. With strong scientific leadership and a differentiated genomics platform, Nucleome is positioned to move promising programmes closer to the clinic.
Ultimately, this leadership addition supports the company’s mission to translate advanced human genetics into meaningful therapies that improve patients’ lives.
Read Also: HanchorBio FDA Orphan Drug Designation Boosts HCB101 for Gastric Cancer
